Farewell, DNA – the Roche takeover of Genentech is a done deal. What will this do to the culture of both companies, I wonder?
DiabetesTV? Forbes explains.
Good news for Amylin and Eli Lilly on Byetta – no cardiovascular risks found. Eli Lilly & Co. and Amylin Pharmaceuticals Inc.’s diabetes drug Byetta wasn’t linked to more heart attacks, strokes or other cardiovascular side effects in an analysis of studies requested by U.S. regulators. The data will be used to support the safety of a once- weekly form of Byetta, which is now given twice a day, the companies said today in a statement. The Food and Drug Administration asked for additional data on the new version of the drug in November.
PLUS – my thoughts on Why Pharma WILL embrace New/Rich/Social Media.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff